Education
About Us
Working with TipRanks
Follow Us
Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
Total Valuation
Suven Pharmaceuticals Ltd. has a market cap or net worth of ₹116.19B. The enterprise value is ₹119.68B.
Market Cap₹116.19B
Enterprise Value₹119.68B
Share Statistics
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding382,567,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Suven Pharmaceuticals Ltd.’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 15.72%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)15.72%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee10.04M
Profits Per Employee2.88M
Employee Count1,193
Asset Turnover0.40
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Suven Pharmaceuticals Ltd. is 52.1. Suven Pharmaceuticals Ltd.’s PEG ratio is -9.48.
PE Ratio52.1
PS Ratio23.00
PB Ratio16.23
Price to Fair Value16.23
Price to FCF207.95
Price to Operating Cash Flow0.00
PEG Ratio-9.48
Income Statement
In the last 12 months, Suven Pharmaceuticals Ltd. had revenue of 11.98B and earned 2.68B in profits. Earnings per share was 10.52.
Revenue11.98B
Gross Profit8.22B
Operating Income5.66B
Pretax Income3.44B
Net Income2.68B
EBITDA4.06B
Earnings Per Share (EPS)10.52
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Suven Pharmaceuticals Ltd. pays an annual dividend of ₹5, resulting in a dividend yield of ―
Dividend Per Share₹5
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change-74.15%
50-Day Moving Average410.81
200-Day Moving Average766.23
Relative Strength Index (RSI)27.29
Average Volume (3m)116.47K
Important Dates
Suven Pharmaceuticals Ltd. upcoming earnings date is May 28, 2026, TBA (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateMay 28, 2026
Ex-Dividend Date―
Financial Position
Suven Pharmaceuticals Ltd. as a current ratio of 2.43, with Debt / Equity ratio of 11.90%
Current Ratio2.43
Quick Ratio1.98
Debt to Market Cap<0.01
Net Debt to EBITDA0.48
Interest Coverage Ratio45.80
Taxes
In the past 12 months, Suven Pharmaceuticals Ltd. has paid 791.50M in taxes.
Income Tax791.50M
Effective Tax Rate0.23
Enterprise Valuation
Suven Pharmaceuticals Ltd. EV to EBITDA ratio is 68.39, with an EV/FCF ratio of 209.42.
EV to Sales23.16
EV to EBITDA68.39
EV to Free Cash Flow209.42
EV to Operating Cash Flow96.26
Balance Sheet
Suven Pharmaceuticals Ltd. has ₹2.80B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹2.80B billion.
Cash & Marketable Securities₹2.80B
Total Debt₹0.00
Net Cash₹2.80B
Net Cash Per Share₹7.33
Tangible Book Value Per Share₹43.74
Margins
Gross margin is 68.19%, with operating margin of 47.23%, and net profit margin of 22.37%.
Gross Margin68.19%
Operating Margin47.23%
Pretax Margin28.72%
Net Profit Margin22.37%
EBITDA Margin33.87%
EBIT Margin27.40%
Analyst Forecast
The average price target for Suven Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast88.74%
EPS Growth Forecast-14.95%